Amgen Rivals Teva With Rituximab Approved For RA
US Market Composed Of Three Biosimilars Plus Rituxan
Amgen has added a further treatment for inflammatory diseases to its vast portfolio, with the FDA approving its rituximab biosimilar Riabni for rheumatoid arthritis.
